Improve cognition through brain stimulation
- Trial ID
- NCT06399731
- Official Title
- NEuroStimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease: an Acceptability Cross-over Study
- Goal
- Improve cognition through brain stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Amsterdam UMC
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson Disease, Mild Cognitive Impairment
- Interventions
- High-frequency (10Hz) rTMS, Anodal tDCS
Plain-Language Summary
The goal is to see whether noninvasive brain stimulation is acceptable to people with Parkinson's and can help mild cognitive problems by improving the brain circuits that support thinking. The trial uses a cross-over design so participants try both high-frequency 10 Hz rTMS, which delivers magnetic pulses to boost activity in targeted brain areas, and anodal tDCS, which applies a gentle direct electrical current to increase neuronal excitability; both are meant to support cognition while participants remain on their usual Parkinson medications. They are looking for people with neurologist-diagnosed Parkinson's and mild cognitive impairment (for example MoCA 21,25 or mild deficits on neuropsychological tests), Hoehn and Yahr stage under 4, and stable dopaminergic meds; people with dementia, seizure history, implanted devices, certain skin or medical conditions, pregnancy, or MRI contraindications are excluded.
Locations
- Amsterdam UMC, Amsterdam, North Holland, Netherlands
Frequently Asked Questions
- What is this trial testing?
- This trial is studying High-frequency (10Hz) rTMS. The goal is to see whether noninvasive brain stimulation is acceptable to people with Parkinson's and can help mild cognitive problems by improving the brain circuits that support thinking. The trial uses a cross-over design so participants try both high-frequency 10 Hz rTMS, which delivers magnetic pulses to boost activity in targeted brain areas, and anodal tDCS, which applies a gentle direct electrical current to increase neuronal excitability; both are meant to support cognition while participants remain on their usual Parkinson medications. They are looking for people with neurologist-diagnosed Parkinson's and mild cognitive impairment (for example MoCA 21,25 or mild deficits on neuropsychological tests), Hoehn and Yahr stage under 4, and stable dopaminergic meds; people with dementia, seizure history, implanted devices, certain skin or medical conditions, pregnancy, or MRI contraindications are excluded.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 6 months.